Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Placebo-controlled, Phase 2 Study of HQK-1001 in Sickle Cell Disease

NCT01601340 is registered in ClinicalTrials.gov with HemaQuest Pharmaceuticals Inc. as lead sponsor.

NCT NCT01601340
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01601340 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Placebo-controlled, Phase 2 Study of HQK-1001 in Sickle Cell Disease
Lead sponsor
HemaQuest Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 31, 2012
Completion date
December 31, 2013
Enrollment
77 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hemoglobin s disease, sickle cell anemia, sickle cell disease, sickle cell disorders, sickling disorder due to hemoglobin s